# A Study to Assess the Safety and Efficacy of Leuprorelin in Central Precocious Puberty in Chinese Participants

> **NCT02427958** · PHASE4 · COMPLETED · sponsor: **Takeda** · enrollment: 307 (actual)

## Conditions studied

- Central Precocious Puberty

## Interventions

- **DRUG:** Leuprorelin

## Key facts

- **NCT ID:** NCT02427958
- **Lead sponsor:** Takeda
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE4
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2015-08-07
- **Primary completion:** 2018-11-23
- **Final completion:** 2018-11-23
- **Target enrollment:** 307 (ACTUAL)
- **Last updated:** 2022-03-16


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02427958

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02427958, "A Study to Assess the Safety and Efficacy of Leuprorelin in Central Precocious Puberty in Chinese Participants". Retrieved via AI Analytics 2026-05-27 from https://api.ai-analytics.org/clinical/NCT02427958. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*